Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
ANNALS OF ONCOLOGY (2012)
期刊
ANNALS OF ONCOLOGY
卷 23, 期 3, 页码 547-555出版社
OXFORD UNIV PRESS
关键词
类别
作者
我是这篇论文的作者
推荐
Breast Cancer: Impact of New Treatments?
Guy A. Storme
CANCERS (2023)
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes
Louise Rethacker, Maxime Boy, Valeria Bisio, France Roussin, Jordan Denizeau, Anne Vincent-Salomon, Edith Borcoman, Christine Sedlik, Eliane Piaggio, Antoine Toubert, Nicolas Dulphy, Anne Caignard
ONCOIMMUNOLOGY (2022)
Honeybee Venom Synergistically Enhances the Cytotoxic Effect of CNS Drugs in HT-29 Colon and MCF-7 Breast Cancer Cell Lines
Diana Duarte, Soraia Falcao, Iouraouine El Mehdi, Miguel Vilas-Boas, Nuno Vale
PHARMACEUTICS (2022)
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig C. Earle, Maureen Trudeau, Kelvin K. W. Chan
JAMA ONCOLOGY (2022)
Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer
Maximillian Viera, George Wai Cheong Yip, Han-Ming Shen, Gyeong Hun Baeg, Boon Huat Bay
CANCERS (2021)
Microgravity: New aspect for breast cancer treatment, a review
Medha Medha, Amit Roy
ACTA ASTRONAUTICA (2022)
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popovic, Tajana Silovski, Marija Krizic, Natalija Dedic Plavetic
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
T. Grinda, A. Antoine, W. Jacot, C. Blaye, P-H Cottu, V Dieras, F. Dalenc, A. Goncalves, M. Debled, A. Patsouris, M-A Mouret-Reynier, A. Mailliez, F. Clatot, C. Levy, J-M Ferrero, I Desmoulins, L. Uwer, T. Petit, C. Jouannaud, M. Lacroix-Triki, E. Deluche, M. Robain, C. Courtinard, T. Bachelot, E. Brain, D. Perol, S. Delaloge
ESMO OPEN (2021)
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn, Shou-Ching Tang
CANCER AND METASTASIS REVIEWS (2022)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)
Clinical Reasoning: New-Onset Diplopia and Headache in a Patient With Metastatic Breast Cancer
Skylar A. Rizzo, Eoin P. Flanagan, Jorge A. Trejo-Lopez, Michel Toledano, Nicholas H. Chia
NEUROLOGY (2023)
The metastatic spread of breast cancer accelerates during sleep
Zoi Diamantopoulou, Francesc Castro-Giner, Fabienne Dominique Schwab, Christiane Foerster, Massimo Saini, Selina Budinjas, Karin Strittmatter, Ilona Krol, Bettina Seifert, Viola Heinzelmann-Schwarz, Christian Kurzeder, Christoph Rochlitz, Marcus Vetter, Walter Paul Weber, Nicola Aceto
NATURE (2022)
New drugs for the treatment of metastatic colorectal cancer
Sara Cherri, Michela Libertini, Alberto Zaniboni
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
Shelby A. Fertal, Johanna E. Poterala, Suzanne M. Ponik, Kari B. Wisinski
CANCERS (2022)
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
C. Sessa, J. Balmana, S. L. Bober, M. J. Cardoso, N. Colombo, G. Curigliano, S. M. Domchek, D. G. Evans, D. Fischerova, N. Harbeck, C. Kuhl, B. Lemley, E. Levy-Lahad, M. Lambertini, J. A. Ledermann, S. Loibl, K. -A. Phillips, S. Paluch-Shimon
ANNALS OF ONCOLOGY (2023)
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
CLINICAL LUNG CANCER (2023)
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
JOURNAL OF CLINICAL ONCOLOGY (2023)
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
LANCET (2023)
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano
BRITISH JOURNAL OF CANCER (2023)
HER2-Low Breast Cancer: a New Subtype?
Chiara Corti, Federica Giugliano, Eleonora Nicolo, Paolo Tarantino, Carmen Criscitiello, Giuseppe Curigliano
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
Pamela Trillo, Jose Sandoval, Dario Trapani, Eleonora Nicolo, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano
EUROPEAN JOURNAL OF CANCER (2023)
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano
EXPERT OPINION ON PHARMACOTHERAPY (2023)
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
GENES (2023)
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Giuseppe Curigliano
CANCERS (2023)
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
Federica Giugliano, Ambra Carnevale Schianca, Chiara Corti, Mariia Ivanova, Nadia Bianco, Silvia Dellapasqua, Carmen Criscitiello, Nicola Fusco, Giuseppe Curigliano, Elisabetta Munzone
CANCERS (2023)
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Giuseppe Curigliano, Carmen Criscitiello
CELLS (2023)
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
NPJ BREAST CANCER (2023)
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
Carmine Valenza, Beatrice Taurelli Salimbeni, Celeste Santoro, Dario Trapani, Gabriele Antonarelli, Giuseppe Curigliano
CANCERS (2023)
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Eleonora Nicolo, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)